The platelet-to-lymphocyte ratio, a blood inflammatory marker that can be calculated based on the results of a simple blood test, may be used as a biomarker of disability severity in people with neuromyelitis optica spectrum disorder (NMOSD), a small study showed. Researchers identified four other ratios, calculated based on…

Blood levels of markers of brain cell damage may be used to distinguish between attack and remission periods in neuromyelitis optica spectrum disorder (NMOSD) patients, but analysis of these blood biomarkers should be done at specific times to get the best accuracy. Those are the findings from a study…

Certain long non-coding RNAs (lncRNAs) — a family of molecules that can regulate gene activity — tied to immune function were at significantly higher levels in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with the general population, a study reports. All four evaluated markers —…

Glial fibrillary acidic protein (GFAP) and the ubiquitin carboxy-terminal hydrolase L1 (UCHL1) enzyme appear to get shed into the bloodstream in the early stages of neuromyelitis optica spectrum disorder (NMOSD), a study found — suggesting that these blood proteins may one day be used to diagnose the autoimmune disease…

People with neuromyelitis optica spectrum disorder (NMOSD) have increased levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of three inflammatory biomarkers, a new study shows. The elevated concentrations of these biomarkers — YKL-40, sCD163, and sCD14 — also…

Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…